News AnGes, Inc.

Equities

4563

JP3127700007

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-31 am EDT			5-day change	1st Jan Change
46 ^JPY	-.--%		-2.13%	-36.11%

Jan. 19	Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease	MT
Jan. 18	Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AnGes : Tie2 receptor agonist (AV 001), co development product, received fast track designation from the U.S. FDA	May. 28	PU
AnGes : Notice of Launch Date for Zokinvy (Orphan Drug) for the Treatment of Progeria	May. 22	PU
AnGes : Consolidated Financial Report for the First Quarter 2024	May. 10	PU
AnGes : Notice Regarding the Decision to Sell the ZOKINVY Business of Eiger BioPharmaceuticals, Inc.	May. 08	PU
AnGes : Notice on the NHI Drug Price Standard Listing and Launch Schedule of Zokinvy for the Treatment of Progeria	Apr. 17	PU
AnGes : Notice Regarding Eiger BioPharmaceuticals, Inc.	Apr. 12	PU
AnGes : Notice of Business Restructuring at Consolidated Subsidiary	Mar. 15	PU
AnGes : Notice of Conclusion of License Agreement and Revision of Consolidated Financial Results Forecast for FY2024	Mar. 14	PU
Eiger and Partner, AnGes, Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	Jan. 19	AQ
Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease	Jan. 19	MT
Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	Jan. 18	CI
Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study	Nov. 14	CI
AnGes : Consolidated Financial Report for the Third Quater 2023	Nov. 07	PU
AnGes : Notice Regarding the Start of Administration of NF-κB Decoy Oligo DNA for the Treatment of Chronic Intervertebral Disc Lumbago in a Phase II Clinical Trial in Japan	23-10-18	PU
AnGes : Consolidated Financial Report Q2 2023	23-08-09	PU
AnGes : Consolidated Financial Report for the Second Quater 2023	23-08-09	PU
Tupperware Brands Corporation : Plastic is fantastic	23-08-08
AnGes : Clinical Research Laboratory has now established "Genetic Testing" technology and aims to begin accepting orders for "genetic testing" in winter 2023	23-07-23	PU
AnGes : Begin contracted expanded newborn screening from municipalities and related institutions from April 2024 at AnGes Clinical Research Laboratory	23-07-18	PU
AnGes : Begin contracted expanded newborn screening from municipalities and related institutions from April 2024 on AnGes Clinical Research Laboratory	23-07-18	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AnGes, Inc.

Equities

4563

JP3127700007

Summary

Filters